139 related articles for article (PubMed ID: 30117091)
1. Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients.
Cao Y; Chang Q; Cabanero M; Zhang W; Hafezi-Bakhtiari S; Hedley D; Darling G; Quereshy F; Jang R; Elimova E; Knox J; Ornatsky O; Serra S; Chen E
J Gastrointest Cancer; 2019 Dec; 50(4):801-807. PubMed ID: 30117091
[TBL] [Abstract][Full Text] [Related]
2. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
[TBL] [Abstract][Full Text] [Related]
3. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
4. Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction.
Sunde B; Ericson J; Kumagai K; Lundell L; Tsai JA; Lindblad M; Rouvelas I; Friesland S; Wang N; Nilsson M
Dis Esophagus; 2016 Jul; 29(5):442-7. PubMed ID: 25809837
[TBL] [Abstract][Full Text] [Related]
5. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
6. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
[TBL] [Abstract][Full Text] [Related]
8. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
9. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
[TBL] [Abstract][Full Text] [Related]
10. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
[TBL] [Abstract][Full Text] [Related]
13. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
15. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
16. [Role of the pathologist in the processing of adenocarcinoma of the stomach, oesophagogastric junction and lower third of the oesophagus].
Svrcek M; Fléjou JF
Ann Pathol; 2011 Dec; 31(6):419-26. PubMed ID: 22172114
[TBL] [Abstract][Full Text] [Related]
17. Staging of adenocarcinoma of the gastroesophageal junction.
Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
[TBL] [Abstract][Full Text] [Related]
18. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
20. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
